We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00543010
First Posted: October 12, 2007
Last Update Posted: June 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
October 5, 2007
October 12, 2007
June 12, 2015
November 2002
November 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00543010 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
Not Provided

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Drug: MK0767
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
247
November 2003
November 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • You are taking at least one medication for high blood sugar
  • Age 21 to 80

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus
  • Currently on estrogen replacement therapy regimen
  • Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
  • Having surgery 30 days before starting the study
  • Have taken any other investigational drug in the past 90 days
  • Have Hepatitis B or C
  • Active liver or gallbladder disease
Sexes Eligible for Study: All
21 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00543010
0767-018
2007_644
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP